Requirement for capital would be the main reason. As always it’s just our capital position that holds us back. Once sorted again we will re rate with FDA trials early next year.
CEO interview on Proactive Investors, page-15
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$12.00 |
Change
-0.190(1.56%) |
Mkt cap ! $253.6M | |||
| Open | High | Low | Value | Volume |
| $12.00 | $13.06 | $11.75 | $459.6K | 38.05K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 5792 | $12.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.70 | 3000 | 1 |
View Market Depth
| Last trade - 16.10pm 02/10/2024 (20 minute delay) ? |
| AVR (ASX) Chart |